While most untransformed cells require substrate attachment for growth (anchorage dependence), the oncogenic transformed cells lack this requirement (anchorage independence) and are often tumorigenic. However, the mechanism of loss of anchorage dependence is not fully understood. When rat normal ®broblasts were cultured in suspension without substrate attachment, the cell cycle arrested in G1 phase and the cyclin-dependent kinase inhibitor p27
Introduction
When the cell cycle of untransformed cells progresses through G1 phase into S phase, the cells alter their responses to mitogenic signals from a dependent state into an independent state. This timing is termed the restriction point, and after this point the cells no longer require the mitogenic signals to progress the cell cycle until the next G1 phase (Sherr, 1993) . Correlated with the restriction point regulation, retinoblastoma protein (Rb) is phosphorylated by the complexes of G1 cyclins and their associated cyclin-dependent kinases (CDKs), and then the transcription factor such as E2F is released from Rb (Sherr, 1994) . To transit through the restriction point, mitogenic signals increase G1 cyclins and thereby activate their associated CDKs (Matsushime et al., 1991; Ko et al., 1992; Won et al., 1992) . These CDK activities are negatively regulated by CDK inhibitors (CKIs). They are divided into two groups, the p21 family [p21 Cip1,Waf1,Sdi1 (Harper et al., 1993; ElDeiry et al., 1993; Xiong et al., 1993) , p27 Kip1 (Polyak et al., 1994b; Toyoshima and Hunter, 1994) , p57
Kip2 Matsuoka et al., 1995) ] and the INK4 family [p15 INK4B, MTS2 (Hannon and Beach, 1994), p16 INK4,MTS1 (Serrano et al., 1993) , p18 (Guan et al., 1994) , p19 (Hirai et al., 1995; Chan et al., 1995) ]. While the p21 family binds to almost all cyclin/CDK complexes and inhibits them, the INK4 family binds to cdk4 and cdk6 and inhibits only their cyclin complexes. Among them, p27
Kip1 is ®rst identi®ed in TGF-b-treated cells (Polyak et al., 1994a) . It accumulates in serum-starved and density-arrested cells and its overexpression causes cell cycle arrest in G1 phase (Polyak et al., 1994b; Toyoshima and Hunter, 1994; Coats et al., 1996) . But increased amounts of p27
Kip1 in quiescent cells decrease upon addition of mitogens (Kato et al., 1994; Nourse et al., 1994) . Thus, in addition to G1 cyclins, p27 Kip1 is also regulated by mitogenic signals.
Substrate attachment is required for untransformed cells to transit through the restriction point. Since the growth of the untransformed cells is anchoragedependent, without substrate attachment the cells cease to proliferate and arrest the cell cycle or commit apoptosis. It is reported that the loss of substrate attachment induces the accumulation of p27
Kip1 (Fang et al., 1996; Zhu et al., 1996) . Thus, p27 Kip1 also plays an important role in the regulation of cell anchorage. On the other hand, many oncogenic transformed cells proliferate anchorage-independently and their growth ability correlates well with their tumorigenicity (Macpherson and Montagnier, 1964; Shin et al., 1975) . Thus, inhibition of the anchorage-independent growth should be an attractive target for cancer chemotherapy. However, the mechanism of the loss of anchorage dependence is not fully understood. We therefore focused on the oncogenic Ras signal as a representative oncogene product, in an attempt to determine how the transformed cells obtain anchorage independence. As a result, we have found that the oncogenic Ras signal accelerates degradation of p27 Kip1 through activation of the MAP kinase signaling pathway.
Results
Oncogenic Ras abrogates cell cycle arrest in G1 phase induced by loss of substrate attachment pMAM-ras-REF is a Fischer rat embryonic ®broblast transformed by dexamethasone (Dex)-inducible v-Kiras. As reported previously (Fukazawa et al., 1995) , in the absence of Dex the cells showed normal phenotypes and could not proliferate in suspended cultures which were assayed using a plate coated with an antiadhesive polymer, polyHEMA (Figure 1a) . On the contrary, by the addition of Dex the cells showed transformed phenotypes and could proliferate in the suspended cultures ( Figure 1a) . We ®rst examined the eect of cell anchorage on the cell cycle progression of pMAM-ras-REF cells. In the absence of Dex the suspended cultures underwent an increase of cells in G1 phase from 71% to 81% and a decrease of those in S phase from 17.1% to 6.5% (Figure 1b) . Furthermore, phosphorylated Rb and H1 kinase activity of cdk2 decreased in the suspended cells (Figure 1c and d) . The amounts of cyclin E, cdk2, and cdk4 were the same regardless of substrate attachment, but the amounts of total and cdk2-bound p27
Kip1 increased in the suspended cells (Figure 1c and e). It is reported that p27
Kip1 and p21
Cip1,Waf1,Sdi1
, but not p57 Kip2 , accumulate in suspended untransformed ®broblasts (Fang et al., 1996; Zhu et al., 1996) ; however, the accumulation of p21 could not be detected in pMAM-ras-REF cells (data not shown). These results indicate that the loss of substrate attachment induces the cell cycle arrest in G1 phase through an increase in p27
Kip1 in pMAM-ras-REF cells. The addition of Dex, on the other hand, induced vKi-Ras expression (Figure 1c ), MAP kinase activation (Figure 1d ), and the cell cycle progression regardless of substrate attachment (Figure 1b) . Concomitantly Rb phosphorylation and cdk2 activity remained high (Figure 1c and d) . Although in the absence of Dex the amount of cyclin D1 was below the detectable level, it was increased by v-Ki-Ras (Figure 1c ). The amounts of cyclin E, cdk4, and cdk2 were not aected ( Figure  1c) . On the contrary, the amounts of total and cdk2-bound p27 were the lowest in the v-Ki-Ras-expressed cells regardless of substrate attachment (Figure 1c and e). These results suggest that the G1-S transition in the suspended cells is induced by the oncogenic Ras signal through down-regulation of p27 Kip1 .
Oncogenic Ras dependent reduction in p27
Kip1
To clarify whether the p27 Kip1 reduction in oncogenic Ras-expressed cells is the response to a direct involvement of Ras in p27
Kip1 regulation or is simply a result of continuous progression of the cell cycle, we examined the eect of time course of v-Ki-Ras expression on the level of p27
Kip1 previously accumulated in the suspended cells without Dex. Upon addition of Dex v-Ki-Ras protein was expressed timedependently, and MAP kinase was at ®rst dramatically activated and thereafter sustained high activity ( Figure  2a ). Conversely, p27
Kip1 was reduced in proportion to the increase in v-Ki-Ras protein with a concomitant increase in Rb phosphorylation and cdk2 activity (Figure 2a) . Thus, it is suggested that v-Ki-Ras reduces the level of p27
Kip1 through the activation of MAP kinase.
Since p27 Kip1 was reduced in the attached cells without Dex, we also examined the eect of time course of cell attachment on p27
Kip1 in the same way. Transferring the suspended cells to attached condition resulted in transient activation of MAP kinase and reduction in p27
Kip1 with a concomitant increase in Rb phosphorylation and cdk2 activity (Figure 2b ). This result also suggests that the activation of MAP kinase down-regulates p27 Kip1 .
Oncogenic Ras accelerates degradation of p27

Kip1
We next examined whether the oncogenic Ras-induced reduction in p27
Kip1 resulted from a decrease in its mRNA or an increase in its protein degradation. For p27
Kip1 mRNA analysis we cloned rat p27 Kip1 cDNA (Genbank accession number D86924) by RT ± PCR as described in Materials and methods since the sequence of rat p27
Kip1 cDNA does not appear in any data base. Total RNA was prepared from pMAM-ras-REF cells cultured in suspension without Dex for 24 h. Cloned rat p27
Kip1 cDNA encoded 197 amino acids and closely resembled mouse and human p27
Kip1 with which it shared 96% and 87% amino acid identity, respectively ( Figure 3 ).
Northern blot analysis of total RNAs from pMAMras-REF cells showed that major p27
Kip1 mRNA was *2.5 kb (Figure 4a ). It is reported that the abundance of p27
Kip1 mRNA is constant between quiescent and proliferating cells (Polyak et al., 1994b; Halevy et al., 1995; Hengst and Reed, 1996) Kip1 protein is not due to inhibition of its protein synthesis. The half-life of p27
Kip1 protein in the suspended cells without Dex, however, was more than 4 h, and that in the attached cells without Dex was about 3 h; it was shortest in the presence of Dex, about 1.5 h (Figure 4b and c). These results demonstrated that p27
Kip1 is up-regulated in mRNA level by loss of substrate attachment, but its degradation is signi®cantly accelerated by oncogenic Ras expression.
Inhibition of MAP kinase activation prevents degradation of p27 Kip1
To con®rm that the MAP kinase cascade is involved in oncogenic Ras-induced p27
Kip1 degradation, we used the agents that raise levels of intracellular cyclic AMP (cAMP), dibutyryl cyclic AMP (dBtcAMP) and forskolin, and a MEK inhibitor. dBtcAMP and forskolin are reported to activate cAMP-dependent protein kinase and inhibit MAP kinase activation through phosphorylation of Raf-1 (Wu et al., 1993; Cook and McCormick, 1993) . PD98059 is a speci®c inhibitor of MEK and also inhibits MAP kinase activation (Dudley et al., 1995) . In pMAM-ras-REF cells v-Ki-Ras-induced MAP kinase activation was completely inhibited by dBtcAMP, forskolin, and PD98059 without signi®cant eect on v-Ki-Ras expression ( Figure 5 ). Although these agents did not aect the amounts of MAP kinase, cyclin E or cdk2, they inhibited v-Ki-Ras-induced p27 Kip1 degradation as well as Rb phosphorylation and cdk2 activation ( Figure 5 ). These results indicate that oncogenic Ras degrades p27
Kip1 through the MAP kinase signaling pathway.
p27
Kip1 is phosphorylated by MAP kinase
It is reported that FAR1, a yeast CKI, is phosphorylated by FUS3, a member of the MAP kinase family (Peter et al., 1993) . We examined whether MAP kinase is able to phosphorylate p27 Kip1 in vitro. As a substrate we used a puri®ed recombinant rat p27
Kip1 tagged with hexahistidine at the C-terminus. Immune complexes precipitated with an anti-MAP kinase phosphorylated p27
Kip1 , but immune complexes precipitated with preimmune serum or without an anti-MAP kinase could not (Figure 6a ). Moreover, activated MAP kinase from oncogenic Ras-expressed cell lysates phosphorylated p27
Kip1 as well as MBP (Figure 6a ). To eliminate the possibility that some contaminating kinase in the immunoprecipitates phosphorylated p27 Kip1 , we conducted an experiment using a puri®ed recombinant MAP kinase. The recombinant MAP kinase phosphorylated p27 Kip1 , but not bovine serum albumin, although the phosphorylation level of p27 Kip1 was signi®cantly lower than that of MBP (Figure 6b ). These results demonstrated that p27
Kip1 is directly phosphorylated by MAP kinase in vitro.
Next we examined whether phosphorylation of p27
Kip1 alters its function, the cdk2 inhibitory activity. As a substrate we prepared p27
Kip1 with dierent degrees in phosphorylation by incubating with MAP kinase immune complexes for various lengths of time Kip1 with dierent degrees in phosphorylation, the recombinant rat p27
Kip1 was incubated for the indicated times with the MAPK immune complexes and both phosphorylation and protein levels of p27 Kip1 were detected by autoradiography and Western blotting (upper panel). These preparations of p27
Kip1 were centrifuged and their supernatants were served for incubation with the cdk2 immune complexes, and then cdk2-bound p27
Kip1 and cdk2 activity were detected as described in Materials and methods (lower panel) p27 kip1 degradation and anchorage independence by Ras M Kawada et al (Figure 6c ). Immune complexes precipitated with an anti-cdk2 were prepared from oncogenic Ras-expressed cells. When these p27
Kip1 were incubated with the cdk2 immune complexes, unphosphorylated p27
Kip1 was coimmunoprecipitated with cdk2 and inhibited the kinase activity, whereas the extent of phosphorylation of p27
Kip1 was found to be inversely proportional to the extent of its co-immunoprecipitation with cdk2 and the inhibition of cdk2 activity. These ®ndings indicate that phosphorylation of p27
Kip1 by MAP kinase disrupts its cdk2 binding activity.
Eect of proteasome inhibitor on degradation of p27 Kip1
It is reported that p27 Kip1 is degraded by the proteasome-dependent pathway in various cell lines (Pagano et al., 1995; Loda et al., 1997) . To determine whether this pathway is involved in the oncogenic Rasinduced p27
Kip1 degradation, we examined the eect of a proteasome inhibitor. MG132 is a potent speci®c proteasome inhibitor and inhibits proteasome-dependent degradation of p53 protein (Jensen et al., 1995; Maki et al., 1996) . LLnL is moderate, and also inhibits calpain, but it inhibits p27
Kip1 degradation in human osteosarcoma cells (Pagano et al., 1995; Jensen et al., 1995; Maki et al., 1996) . In pMAM-ras-REF cells 4 h treatment with MG132 resulted in a marked increase in p53 protein (Figure 7a ). LLnL increased p53 weakly, but E64-d, which is a calpain inhibitor and was used as a negative control, did not increase the p53 level (Figure 7a) . Unexpectedly, however, neither MG132 nor LLnL increased the amount of p27
Kip1 protein in vKi-Ras-expressed cells at concentrations up to 100 mM, which is the toxic dose (Figure 7a) , even if the cells were treated for 24 h (data not shown). On the contrary, when p27
Kip1 degradation was assayed in vitro using a recombinant p27
Kip1 and cell extract from the oncogenic Ras-expressed cells, MG132 completely inhibited the p27 Kip1 degradation (Figure 7b ). But p27 Kip1 was degraded in the cell extract to the same extent regardless of v-Ki-Ras expression, even though it was no longer degraded in the proteasome-depleted cell extract (data not shown).
Discussion
In the presence of substrate attachment p27 Kip1 accumulates in serum-starved untransformed cells, but the addition of fresh serum reduces the level of p27 Kip1 (Kato et al., 1994; Nourse et al., 1994; Schulze et al., 1996) . However, our results and others (Fang et al., 1996; Zhu et al., 1996) have shown that loss of substrate attachment induces the accumulation of p27
Kip1 even in the presence of serum. It has been generally accepted that the mRNA level of p27 Kip1 remains constant regardless of the state of cell growth (Polyak et al., 1994b; Halevy et al., 1995; Hengst and Reed, 1996) . But our results showed that the loss of substrate attachment dramatically increased the amount of p27 Kip1 mRNA. It is reported that the expression of cyclin A controls anchorage dependence (Guadagno et al., 1993; Barrett et al., 1995; Kang and Krauss, 1996) . Recently Schulze et al. (1996) have indicated that p27
Kip1 regulates the expression of cyclin A through inhibition of E2F release from Rb. These ®ndings suggest that up-regulation of p27
Kip1 mRNA is at least one of the mechanism(s) of anchorage dependence. Although the mechanism of up-regulation of p27
Kip1 mRNA is not clear, it is possible that attachment signals, which are considered to be mediated through integrins from extracellular matrix, may suppress the transcription rate. Our recent data revealed that the stability of p27
Kip1 mRNA was not aected by the loss of substrate attachment (data not shown).
To understand how the transformed cells obtain anchorage independence, we used inducible oncogenic Ras transformed cells. Our results demonstrated that oncogenic Ras accelerated the degradation of p27 Kip1 through the MAP kinase signaling pathway. It is reported that mitogenic signals and Ras signals increase the cyclin D1 expression in various cell lines (Matsushime et al., 1991; Won et al., 1992; Liu et al., 1995; Winston et al., 1996) . Our results also showed that v-Ki-Ras expression increased the level of cyclin D1 and this increase was inhibited by cAMP-elevating agents and a MEK inhibitor through MAP kinase inhibition (data not shown). However, many reports indicate that overexpression of cyclin D1 alone cannot confer anchorage-independent growth (Hinds et al., 1994; Lovec et al., 1994; Liu et al., 1995) . Ras signals also activate other pathways, such as PI3-kinase (Rodriguez-Viciana et al., 1994) . But v-Ki-Ras expression could not activate PI3-kinase and wortmannin, a PI3-kinase inhibitor, failed to inhibit the p27 Kip1 was incubated for 3 h with the cell extracts in the presence of protease inhibitors and p27
Kip1 was detected by Western blotting as described in Materials and methods p27 kip1 degradation and anchorage independence by Ras M Kawada et al p27 Kip1 is reduced in oncogenic Ha-Ras-expressed cells (Winston et al., 1996; Kang and Krauss, 1996) . Winston et al. (1996) have shown that growth factorstimulated pathways are required in addition to Ras to reduce the p27 Kip1 level. Kang and Krauss (1996) have suggested that reduction in p27
Kip1 does not directly correlate with anchorage independence, although its expression appeared to be a target of Ras signals. Thus it is yet to be determined whether accelerated degradation of p27
Kip1 is necessary and/or sucient for transformation by Ras. However, our present study suggests that at least the Ras-induced degradation of p27 Kip1 is strongly associated with the anchorageindependent growth in pMAM-ras-REF cells.
It is reported that p27
Kip1 is degraded by the proteasome-dependent pathway (Pagano et al., 1995; Loda et al., 1997) . But unexpectedly, the proteasome inhibitor failed to inhibit the v-Ki-Ras-induced p27 Kip1 degradation, even though it inhibited the degradation of p53 (Figure 7a ) and increased the amount of intracellular ubiquitinated proteins (data not shown). On the contrary, it inhibited the p27 Kip1 degradation in vitro using cell extracts. Moreover, the proteasomedepleted cell extract failed to degrade p27 Kip1 . The results of in vitro experiments suggest that oncogenic Ras signals possibly degrade p27 Kip1 through the proteasome pathway. But regardless of v-Ki-Ras expression the cell extracts degraded p27
Kip1 equally in vitro (data not shown), and the result did not re¯ect the degradation pattern in vivo (Figure 4b and c) . Recently Luo et al. (1996) reported the proteasome-independent pathway of p27 Kip1 degradation. Although the discrepancy of our results between in intact cells and in the cell-free system is not clear, we cannot exclude the possibility that oncogenic Ras signals degrade p27 Kip1 through the proteasome unrelated pathway.
We have found that p27 Kip1 is phosphorylated by MAP kinase in vitro and the phosphorylated p27 Kip1 cannot bind to and inhibit cdk2. These ®ndings suggest that activated MAP kinase increases nonfunctional`free' p27 Kip1 and thus the free p27 Kip1 is easily degraded. Furthermore, it might be possible that activated MAP kinase could release p27
Kip1 from p27 Kip1 -CDK complex through its phosphorylation. There was a time lag between maximum reduction in p27
Kip1 and activation of MAP kinase (Figure 2 ). Although we have not yet compared relative phosphorylation level and timing of p27
Kip1 by MAP kinase with other intracellular substrates of MAP kinase, it is likely that the sustained activation of MAP kinase after the transient activation should be required to degrade p27
Kip1 . Since there are four (S/T)P sites (Ser ) that form the core of the phosphorylation site by MAP kinase (ClarkLewis et al., 1991; Haycock et al., 1992) , we are now studying the phosphorylation of p27
Kip1 in vivo and the phosphorylation site of p27
Kip1 by MAP kinase. Unlike other CKIs, p27
Kip1 gene is rarely deleted or mutated in cancer cells (Ponce-Castaneda et al., 1995; Southgate et al., 1995; Takeuchi et al., 1996; Spirin et al., 1996) . Thus, p27
Kip1 may function as a universal regulator of cell cycle progression in mammalian cells. Recently it has been reported that the p27 Kip1 reduction in tumor cells correlates with their malignancy (Porter et al., 1997; Catzavelos et al., 1997; Loda et al., 1997) . This would mean that the regulatory pathways of p27 Kip1 , both transcriptional and post-transcriptional levels including p27 Kip1 degradation pathway, could be a potential target for cancer drug discovery.
Materials and methods
Reagents and antibodies
dBtcAMP and forskolin were purchased from Sigma. N-
, and [L-3-trans-ethoxycarbonyl-oxirane -2-carbonyl]-L-leucine(3-methylbutyl)amide (E64-d) were obtained from Peptide Institute, Japan. PD98059 was from Calbiochem. Antibodies used for Western blotting were the following: anticdk2 (sc-163), cdk4 (sc-260), cyclin D1 (sc-92), and Rb (sc-15) were from Santa Cruz Biotechnology; anti-p27
Kip1 was from MO Biolaboratories, Transduction Laboratories, or Santa Cruz (sc-528); anti-cyclin E (06-134) was from Upstate Biotechnology; anti-MAP kinase (ERK1+2) was from Zymed (Z033); anti-Ras (RAS10) and p53 (421) were from Oncogene Science. A recombinant murine MAP kinase (Erk2) was purchased from BioLabs.
Cell culture
pMAM-ras-REF is a cloned Fischer rat embryo ®broblast cell line transformed with pMAMneo-v-Ki-ras, a plasmid in which v-Ki-ras is linked to the Dex-inducible MMTV-LTR promoter (Fukazawa et al., 1995) . The cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 100 mg/ml kanamycin at 378C with 5% CO 2 . The exponentially growing cells were trypsinized and resuspended in fresh medium. Then, the cells were inoculated onto polyHEMA-coated (suspended cultures) or uncoated (attached cultures) plates. PolyHEMA-coated plates were prepared as described (Folkman and Moscona, 1978; Fukazawa et al., 1995) . v-Ki-Ras expression in pMAMras-REF cells was induced by 1 mM Dex (Sigma).
Cell cycle analysis
Cells (5610 5 ) were cultured under attached or suspended conditions with or without Dex for 24 h. The cells were trypsinized and ®xed with ice-cold 70% ethanol. The ®xed cells were treated with 0.1% RNase (Sigma) at 378C for 15 min and then resuspended in phosphate-buered saline (PBS) containing 50 mg/ml propidium iodide (Sigma). DNA¯uorescence was measured with a FACScan¯ow cytometer (Becton Dickinson) using CellFIT, a cell-cycle analysis software.
Preparation of cell lysates and Western blotting
Cells (3610 5 ) were washed twice with ice-cold PBS containing 100 mM Na 3 VO 4 and then lysed in a lysis buffer (20 mM HEPES [pH 7.5], 150 mM NaCl, 1% Triton X-100, 10% glycerol, 1 mM EDTA, 50 mM NaF, 50 mM bglycerophosphate, 1 mM Na 3 VO 4 and 25 mg/ml each of antipain, leupeptin and pepstatin). Equal protein extracts were separated by SDS ± PAGE, and transferred onto Immobilon PVDF membranes (Millipore). Enhanced chemiluminescence (Amersham) was used to visualize the immunoblot signals.
Immunoprecipitation and kinase assays
Cell lysates were prepared as described above, and equal amounts of protein were incubated with anti-MAP kinase (sc-93) or anti-cdk2 (sc-163) from Santa Cruz. The immune complexes were collected on protein A-Sepharose beads p27 kip1 degradation and anchorage independence by Ras M Kawada et al (Pharmacia Biotech) and washed four times in IP buer (20 mM HEPES [pH 7.5], 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 50 mM NaF, 50 mM b-glycerophosphate, 0.1 mM PMSF and 0.2 mM Na 3 VO 4 ) and once in a kinase buer (20 mM HEPES [pH 7.5], 10 mM MgCl 2 and 1 mM DTT). The immunoprecipitates were incubated at 378C for 10 min in a kinase buer containing 30 mM ATP, 5 mCi of [g-32 P]ATP and 0.2 mg/ml MBP (Sigma) or 0.06 mg/ml histone H1 (Boehringer Mannheim). The reaction was terminated with SDS sample buer. Phosphorylated substrates were separated by 12.5% SDS ± PAGE, and autoradiographed.
Cloning of rat p27
Kip1 cDNA pMAM-ras-REF cells were cultured in suspension without Dex for 24 h and then total RNA was prepared. First, partial rat p27 Kip1 cDNA was ampli®ed from the total RNA by RT ± PCR using N-and C-terminal regions of a mouse p27
Kip1 cDNA sequence as primers: 5'-GCGGAATTCA-TGTCAAACGTGAGAGT-3' (sense, codon 1 ± 6) and 5'-GCGGAATTCTTACGTCTGGCGTCGAA-3' (antisense, codon 193-STOP). These primers were preceded by EcoRI site to enable subsequent cloning. The product digested with EcoRI was cloned into pUC19 vector and sequenced. The complete sequences for N-and C-terminal regions were determined by RT ± PCR using 5'-RACE and 3'-RACE systems (GIBCO-BRL). For 5'-RACE system 5'-TGGCTCGCTTCTTCCATATC-3' (antisense, codon 51 ± 57) and 5'-GTTCTTCATGATTGACCGGG-3' (nested antisense, codon 35 ± 40) were used as gene-speci®c primers. For 3'-RACE system 5'-GGCAGAAGATTCTTCTTCGC-3' (sense, codon 157 ± 162) and 5'-AAGGGCCAACAGA-ACAGAAG-3' (nested sense, codon 166 ± 171) were used. Products were cloned into pGEM-T vector (Promega) and sequenced. To determine DNA sequence of each RT ± PCR product at least more than 3 clones were sequenced. Cloned rat p27 Kip1 cDNA coding an open reading frame was used as a p27
Kip1 mRNA speci®c probe.
Northern blotting
Cells were cultured under attached or suspended conditions with or without Dex for 24 h. Total RNAs were prepared and equal amounts of RNA samples (15 mg) were separated on 1% agarose formaldehyde gels and transferred to Hybond N + membranes (Amersham) for Northern blot analysis. Probes were labeled by using a random priming kit (Boehringer Mannheim).
Metabolic labeling of cells
Cells (3610 5 ) were washed twice with ice-cold PBS and pulse-labeled in methionine-free minimum essential medium with 200 mCi of 35 S-protein labeling mix (73% [ 35 S]methionine and 22% [
35 S]cysteine; NEN) for 1 h. Then FBS, cold methionine and cysteine were added to ®nal concentrations of 10%, 100 and 150 mg/ml, respectively, and the cells were further incubated for 1, 2, or 4 h. The cell lysates were prepared and equal amounts of protein were immunoprecipitated with anti-p27 Kip1 as described above. The immunoprecipitates were separated by 12.5% SDS ± PAGE and radiolabeled proteins were visualized by Fujix BAS2000 image analyzer.
Preparation of recombinant rat p27 Kip1
An NdeI-XhoI fragment of PCR-ampli®ed rat p27 Kip1 cDNA containing the full-length coding region was subcloned into pET21a (Novagen), yielding a construct that encodes p27
Kip1 tagged with hexahistidine at the Cterminus. The protein was expressed in BL21 bacteria and puri®ed using Ni-NTA resin (Quiagen) as described (Polyak et al., 1994b) .
Phosphorylation of p27
Kip1 MAP kinase immune complexes were prepared as described above and incubated at 378C for 30 min or indicated times in a kinase buer containing 30 mM ATP, 5 mCi of [g-32 P]ATP and 0.1 mg/ml recombinant rat p27 Kip1 or 0.2 mg/ml MBP (Sigma). The reaction was terminated with SDS sample buer. Phosphorylated substrates were separated by 12.5% SDS ± PAGE, and autoradiographed.
p27
Kip1 and cdk2 complex formation assay
Phosphorylated recombinant p27
Kip1 was prepared as described above, diluted (1/40), and incubated with cdk2 immune complexes at 378C for 10 min. The incubated samples were washed with IP buer. Then, cdk2-bound p27 Kip1 and cdk2 activity were detected as described above.
In vitro p27
Kip1 degradation
Cell extract and proteasome-depleted cell extract were prepared as described (Nakajima et al., 1996) . The cell extract was incubated with 36 mg/ml recombinant p27 Kipl in a reaction buer (50 mM Tris-HCl [pH 8.3], 5 mM MgCl 2 , 2 mM DTT, 1 mM ATP, 10 mM phosphocreatine and 40 mg/ml creatine phosphokinase) at 378C for 3 h. The p27
Kip1 was detected by Western blotting.
